BACKGROUND: Thalidomide and its analogs are effective agents in the treatment of multiple myeloma. Since gelatinases (matrix metalloproteinases-2 and -9) play a crucial role in tumor progression, we explored the effect of thalidomide on gelatinase production by malignant B lymphoid cell lines. DESIGN AND METHODS: We investigated the effect of therapeutic doses of thalidomide on integrin-mediated production of gelatinases by malignant B lymphoid cell lines by gelatin zymography, western-blot, reverse transcriptase polymerase chain reaction and invasive capacity through Matrigel-coated Boyden chambers. We also explored the effect of thalidomide on the activation status of the main signaling pathways involved in this process. RESULTS: Thalidomide strongly inhibited gelatinase production by B-cell lines and primary myeloma cells in response to fibronectin, the most efficient gelatinase inducer identified in lymphoid cells. Thalidomide disrupted integrin-mediated signaling pathways involved in gelatinase induction and release, such as Src and MAP-kinase ERK activation, resulting in decreased cell motility and invasiveness. Unexpectedly, treatment with thalidomide elicited an increase in fibronectin-induced Akt phosphorylation through phosphoinositide 3-kinase-independent pathways since thalidomide decreased fibronectin-induced phosphoinositide 3-kinase phosphorylation and reversed the inhibition of Akt phosphorylation achieved by the phosphoinositide 3-kinase inhibitors wortmannin and LY294002. CONCLUSIONS: Disruption of integrin-mediated signaling may be an important mechanism through which thalidomide and its analogs impair tumor cell interactions with the microenvironment. The unexpected effects of thalidomide on Akt activation indicate the need for further studies to elucidate whether the interference with Akt downstream effects would synergize with the anti-tumor activity of thalidomide.
BACKGROUND:Thalidomide and its analogs are effective agents in the treatment of multiple myeloma. Since gelatinases (matrix metalloproteinases-2 and -9) play a crucial role in tumor progression, we explored the effect of thalidomide on gelatinase production by malignant B lymphoid cell lines. DESIGN AND METHODS: We investigated the effect of therapeutic doses of thalidomide on integrin-mediated production of gelatinases by malignant B lymphoid cell lines by gelatin zymography, western-blot, reverse transcriptase polymerase chain reaction and invasive capacity through Matrigel-coated Boyden chambers. We also explored the effect of thalidomide on the activation status of the main signaling pathways involved in this process. RESULTS:Thalidomide strongly inhibited gelatinase production by B-cell lines and primary myeloma cells in response to fibronectin, the most efficient gelatinase inducer identified in lymphoid cells. Thalidomide disrupted integrin-mediated signaling pathways involved in gelatinase induction and release, such as Src and MAP-kinase ERK activation, resulting in decreased cell motility and invasiveness. Unexpectedly, treatment with thalidomide elicited an increase in fibronectin-induced Akt phosphorylation through phosphoinositide 3-kinase-independent pathways since thalidomide decreased fibronectin-induced phosphoinositide 3-kinase phosphorylation and reversed the inhibition of Akt phosphorylation achieved by the phosphoinositide 3-kinase inhibitors wortmannin and LY294002. CONCLUSIONS: Disruption of integrin-mediated signaling may be an important mechanism through which thalidomide and its analogs impair tumor cell interactions with the microenvironment. The unexpected effects of thalidomide on Akt activation indicate the need for further studies to elucidate whether the interference with Akt downstream effects would synergize with the anti-tumor activity of thalidomide.
Authors: Robert T Abbott; Sheryl Tripp; Sherrie L Perkins; Kojo S J Elenitoba-Johnson; Megan S Lim Journal: Mod Pathol Date: 2003-06 Impact factor: 7.842
Authors: F Bertolini; W Mingrone; A Alietti; P F Ferrucci; E Cocorocchio; F Peccatori; S Cinieri; P Mancuso; C Corsini; A Burlini; E Zucca; G Martinelli; S Cineri Journal: Ann Oncol Date: 2001-07 Impact factor: 32.976
Authors: Shaji Kumar; Rafael Fonseca; Angela Dispenzieri; Martha Q Lacy; John A Lust; Linda Wellik; Thomas E Witzig; Morie A Gertz; Robert A Kyle; Philip R Greipp; S Vincent Rajkumar Journal: Blood Date: 2002-10-17 Impact factor: 22.113
Authors: Datsun A Hsia; Satyajit K Mitra; Christof R Hauck; Daniel N Streblow; Jay A Nelson; Dusko Ilic; Shuang Huang; Erguang Li; Glen R Nemerow; Jay Leng; Kathryn S R Spencer; David A Cheresh; David D Schlaepfer Journal: J Cell Biol Date: 2003-03-03 Impact factor: 10.539
Authors: Maroun Bou Zerdan; Lewis Nasr; Joseph Kassab; Ludovic Saba; Myriam Ghossein; Marita Yaghi; Barbara Dominguez; Chakra P Chaulagain Journal: Int J Hematol Oncol Date: 2022-04-26